|
시장보고서
상품코드
2151965
Pharma 5.0 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Pharma 5.0 Market Size, Share & Trends Analysis Report By Type, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Pharma 5.0 시장 요약
세계 Pharma 5.0 시장 규모는 2025년 79억 달러로 평가되며, 2026년 94억 달러에서 2033년까지 376억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지의 연평균 성장률(CAGR)은 21.9%에 달할 것으로 전망됩니다.
북미가 시장을 주도하고 있으며, 2025년 매출 점유율은 43.1%를 차지했습니다. 시장의 성장은 의약품 혁신, 업무 효율성 및 환자 중심 치료를 강화하기 위한 AI, 디지털 트윈, 첨단 로봇 공학, 유전체학, 지능형 공급망 솔루션 및 지속가능한 제조 기술의 도입 확대에 의해 주도되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 시장 : 변수, 동향, 범위
- 시장 계보 전망
- 시장 역학
- 업계 분석 도구
제4장 유형별 비즈니스 분석
- Pharma 5.0 시장 : 유형별 동향 분석
- 소프트웨어
- 서비스
제5장 기술별 비즈니스 분석
- Pharma 5.0 시장 : 기술별 동향 분석
- 인공지능(AI) 및 생성형 AI
- 디지털 트윈 및 공정 시뮬레이션 기술
- 유전체학 및 멀티오믹스 기술
- 첨단 로봇공학
- 지능형 공급망 기술
- 지속가능한 제조 기술
- 기타(AR, VR, MR, 커넥티드 워크포스 기술)
제6장 용도별 비즈니스 분석
- Pharma 5.0 시장 : 용도별 동향 분석
- 신약 개발
- 스마트 제조 및 공정 최적화
- 맞춤형 의료의 개발 및 제조
- 공급망 관리 및 물류
- 품질 관리 및 규제 준수
- 지속가능성과 자원 최적화
제7장 최종 용도별 비즈니스 분석
- Pharma 5.0 시장 : 최종 용도별 동향 분석
- 제약 회사
- 생명공학 기업
- CDMO
- CRO
- 학술 연구 기관
제8장 지역별 비즈니스 분석
- Pharma 5.0 시장 점유율 : 지역별, 2025년 및 2033년
- 북미
- 북미 Pharma 5.0 시장, 2021-2033년
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽의 Pharma 5.0 시장, 2021-2033년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 아시아태평양의 Pharma 5.0 시장, 2021-2033년
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 라틴아메리카의 Pharma 5.0 시장, 2021-2033년
- 브라질
- 아르헨티나
- 중동 및 아프리카
- MEA의 Pharma 5.0 시장, 2021-2033년
- 남아프리카
- 사우디아라비아
- UAE
- 쿠웨이트
제9장 경쟁 현황
- 기업 분류
- 기업 점유율 및 포지셔닝 분석, 2025년
- 전략 매핑
- 기업 개요 및 목록
- NVIDIA Corporation
- Microsoft
- Siemens
- Dassault Systemes
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- ABB
- SAP SE
- Blue Yonder Group, Inc.(Acquired By Panasonic Holdings Corporation)
- IBM
- IQVIA Inc.
- Merck KGaA
- Relay Therapeutics
- Certara
- XtalPi
Pharma 5.0 Market Summary
The global pharma 5.0 market size was valued at USD 7.9 billion in 2025 and is projected to grow from USD 9.4 billion in 2026 to USD 37.6 billion by 2033, at a CAGR of 21.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.1% in 2025. The market growth is driven by the increasing adoption of AI, digital twins, advanced robotics, genomics, intelligent supply chain solutions, and sustainable manufacturing technologies to enhance pharmaceutical innovation, operational efficiency, and patient-centric care.
Global Pharma 5.0 Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Pharma 5.0 market report based on type, technology, application, end-use, and region:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Software
- Services
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Artificial Intelligence (AI) & Generative AI
- Digital Twin & Process Simulation Technologies
- Genomics & Multi-omics Technologies
- Advanced Robotics
- Intelligent Supply Chain Technologies
- Sustainable Manufacturing Technologies
- Others (AR, VR, MR, Connected Workforce Technologies)
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Drug Discovery & Development
- Smart Manufacturing & Process Optimization
- Personalized Medicine Development & Manufacturing
- Supply Chain Management & Logistics
- Quality Management & Regulatory Compliance
- Sustainability & Resource Optimization
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical Companies
- Biotechnology Companies
- CDMOs
- CROs
- Academic & Research Institutes
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Type Segment
- 1.1.1.2. Technology Segment
- 1.1.1.3. Application Segment
- 1.1.1.4. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. List of Secondary Sources
- 1.9.3. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Expansion of Digital Twins and Simulation Technologies
- 3.2.1.2. Growing Adoption of AI and Generative AI
- 3.2.1.3. Advancements in Genomics and Multi-Omics Technologies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Data Privacy and Cybersecurity Concerns
- 3.2.2.2. Complex Regulatory Requirements For AI-Driven Technologies
- 3.2.3. Market Opportunities Analysis
- 3.2.4. Market Challenges Analysis
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Economic landscape
- 3.3.2.5. Legal landscape
- 3.3.1. Porter's Five Forces Analysis
Chapter 4. Type Business Analysis
- 4.1. Segment Dashboard
- 4.2. Pharma 5.0 Market: Type Movement Analysis
- 4.3. Software
- 4.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 4.4. Services
- 4.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 5. Technology Business Analysis
- 5.1. Segment Dashboard
- 5.2. Pharma 5.0 Market: Technology Movement Analysis
- 5.3. Artificial Intelligence (AI) & Generative AI
- 5.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.4. Digital Twin & Process Simulation Technologies
- 5.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.5. Genomics & Multi-omics Technologies
- 5.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.6. Advanced Robotics
- 5.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.7. Intelligent Supply Chain Technologies
- 5.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.8. Sustainable Manufacturing Technologies
- 5.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 5.9. Others (AR, VR, MR, Connected Workforce Technologies)
- 5.9.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 6. Application Business Analysis
- 6.1. Segment Dashboard
- 6.2. Pharma 5.0 Market: Application Movement Analysis
- 6.3. Drug Discovery & Development
- 6.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.4. Smart Manufacturing & Process Optimization
- 6.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.5. Personalized Medicine Development & Manufacturing
- 6.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.6. Supply Chain Management & Logistics
- 6.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.7. Quality Management & Regulatory Compliance
- 6.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 6.8. Sustainability & Resource Optimization
- 6.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 7. End Use Business Analysis
- 7.1. Segment Dashboard
- 7.2. Pharma 5.0 Market: End Use Movement Analysis
- 7.3. Pharmaceutical Companies
- 7.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.4. Biotechnology Companies
- 7.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.5. CDMOs
- 7.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.6. CROs
- 7.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
- 7.7. Academic & Research Institutes
- 7.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
Chapter 8. Regional Business Analysis
- 8.1. Pharma 5.0 Market Share By Region, 2025 & 2033
- 8.2. North America
- 8.2.1. North America Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Competitive Scenario
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. U.S. Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Competitive Scenario
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Canada Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Competitive Scenario
- 8.2.4.3. Regulatory Framework
- 8.2.4.4. Mexico Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Competitive Scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. UK Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Competitive Scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Germany Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Competitive Scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. France Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Competitive Scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Italy Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Competitive Scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Spain Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Competitive Scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Denmark Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Competitive Scenario
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Sweden Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Competitive Scenario
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Norway Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Japan Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. China Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. India Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.5. Australia
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Competitive Scenario
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. Australia Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.6. Thailand
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Competitive Scenario
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Thailand Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.4.7. South Korea
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Competitive Scenario
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. South Korea Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Brazil Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Argentina Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.6. MEA
- 8.6.1. MEA Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. South Africa Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Saudi Arabia Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. UAE Pharma 5.0 Market, 2021 - 2033 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Kuwait Pharma 5.0 Market, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Company Market Share/ Position Analysis, 2025
- 9.3. Strategy Mapping
- 9.4. Company Profiles/Listing
- 9.4.1. NVIDIA Corporation
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product/Service Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. Microsoft
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product/Service Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Siemens
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product/Service Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Dassault Systemes
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product/Service Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Illumina, Inc.
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product/Service Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Thermo Fisher Scientific Inc.
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product/Service Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. ABB
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product/Service Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. SAP SE
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product/Service Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Blue Yonder Group, Inc. (Acquired By Panasonic Holdings Corporation)
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product/Service Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. IBM
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product/Service Benchmarking
- 9.4.10.4. Strategic Initiatives
- 9.4.11. IQVIA Inc.
- 9.4.11.1. Overview
- 9.4.11.2. Financial Performance
- 9.4.11.3. Product/Service Benchmarking
- 9.4.11.4. Strategic Initiatives
- 9.4.12. Merck KGaA
- 9.4.12.1. Overview
- 9.4.12.2. Financial Performance
- 9.4.12.3. Product/Service Benchmarking
- 9.4.12.4. Strategic Initiatives
- 9.4.13. Relay Therapeutics
- 9.4.13.1. Overview
- 9.4.13.2. Financial Performance
- 9.4.13.3. Product/Service Benchmarking
- 9.4.13.4. Strategic Initiatives
- 9.4.14. Certara
- 9.4.14.1. Overview
- 9.4.14.2. Financial Performance
- 9.4.14.3. Product/Service Benchmarking
- 9.4.14.4. Strategic Initiatives
- 9.4.15. XtalPi
- 9.4.15.1. Overview
- 9.4.15.2. Financial Performance
- 9.4.15.3. Product/Service Benchmarking
- 9.4.15.4. Strategic Initiatives
- 9.4.1. NVIDIA Corporation
